The guidance breaks down the indication discussion into three groupings: condition-specific indications, group-specific indications, and general chronic pain claims. (Shutterstock)
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
